NDAORALSOLUTION
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ONTRALFY (tizanidine hydrochloride) by Biofidelity is alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. Approved for spasticity in adults. First approved in 2024.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONTRALFY is an oral solution formulation of tizanidine hydrochloride, an alpha-2-adrenergic receptor agonist approved in December 2024 for treating spasticity in adults. It works by increasing presynaptic inhibition of motor neurons, with greatest effects on polysynaptic pathways to reduce spinal motor neuron facilitation. This is a newly approved NDA product entering the growth phase of its lifecycle.
Growth15.5 years to LOE
Early-stage growth product with 15.5 years of patent protection offers stable career trajectory with opportunity to build market presence against established competitors.
Mechanism of Action
alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
Indications (1)
Career Relevance
ONTRALFY represents a launch-stage growth opportunity in a competitive spasticity market where success depends on differentiating a formulation-identical product through market access, payer strategy, and field execution. Career roles will focus on rapid market penetration, physician education, and defending against incumbent ZANAFLEX while building sustainable market share before generic competition in 2042.
Worked on ONTRALFY at Biofidelity? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.